Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...
Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high-growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% ...
Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...
Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...
Feb 24 (Reuters) - Hims & Hers (HIMS.N), opens new tab said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk (NOVOb.CO), opens new ...
HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While ...
Hims & Hers Health, Inc. (NYSE:HIMS) stock is trading lower on Wednesday, with a session volume of 7.7 million compared to the average volume of 19.34 million, as per data from Benzinga Pro.
Bullish option flow detected in Hims and Hers Health with 70,176 calls trading, 5x expected, and implied vol increasing almost 17 points to 144.53%. Feb-25 36 calls and Feb-25 70 calls are the ...